date:Aug 11, 2021
Israeli bio-pharmaceutical company Mileutis is preparing for the final commercialization stages for Imilac, a solution that helps dairy cows avoid antibiotic resistance. The company forecasts that future applications of its solution can reduce the usage of antibiotics in dairy farms by up to 90 percent.
The active ingredient in Mileutiss Imilac, is a unique proprietary immunomodulator a collection of peptides derived from natural bovine casein hydrolysate (bCNH), the main protein in cow milk.